Patents Assigned to Merck
  • Micromixer
    Patent number: 6457854
    Abstract: The inventive micromixer for mixing liquid, viscous or gaseous phases has a housing bottom part (2) and a housing top part (3) which lie closely against each other via connecting surfaces (6, 7). Two delivery channels (1a, 1b) and an outlet channel (5) open out into the dividing surface between the two connecting surface (6, 7). Channel grooves (9, 10) which cross each other several times are formed in one connecting surfaces (6) and provide a mixing section for the phases being mixed.
    Type: Grant
    Filed: April 24, 2000
    Date of Patent: October 1, 2002
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Ulrich Koop, Michael Schmelz, Andreas Beirau
  • Micro mixer
    Patent number: 6457855
    Abstract: A micro mixer for liquid, viscous or gaseous phases with two adjacent housing parts (1,2) disposed on a parting plane (3). Capillary tubes (7) forming line connections are inserted into cross holes (6) in the top part of the housing (1) by welding, for instance, and run into the parting plane (3). The other free ends of the capillary tubes (7) are bent apart and respectively bear a screw connection.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: October 1, 2002
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Andreas Beirau, Michael Schmelz, Frank Schwarz, Jöran Stoldt
  • Tetrahydropyran derivatives and their use as therapeutic agents
    Patent number: 6458830
    Abstract: The present invention relates to compounds of the formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis and postherpetic neuralgia.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: October 1, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Simon Neil Owen, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Radiolabeled farnesyl-protein transferase inhibitors
    Patent number: 6458935
    Abstract: The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: October 1, 2002
    Assignee: Merck & Co., Inc.
    Inventors: H. Donald Burns, Terence G. Hamill, Raymond E. Gibson
  • Substituted piperidines as melanocortin receptor agonists
    Patent number: 6458790
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment and control of obesity, diabetes, and sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 1, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Brenda L. Palucki, Khaled J. Barakat, Liangqin Guo, Yingjie Lai, Ravi P. Nargund, Min K. Park, Patrick G. Pollard, Iyassu K. Sebhat, Zhixiong Ye
  • Cyclohexane derivatives and liquid-crystalline medium
    Publication number: 20020134967
    Abstract: The invention relates to cyclohexane derivatives of the formula I 1
    Type: Application
    Filed: June 28, 2001
    Publication date: September 26, 2002
    Applicant: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Peer Kirsch, Joachim Krause, Michael Heckmeier
  • Wet granulation formulation for bisphosphonic acids
    Publication number: 20020137727
    Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by wet granulation tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease. These compositions are prepared without the addition of binder; instead, the drug itself acts as a binder.
    Type: Application
    Filed: March 4, 2002
    Publication date: September 26, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Ashok V. Katdare, Kenneth A. Kramer
  • Protein tyrosine phosphatase-1B (PTP-1B) deficient mice and assays for PTP-1B modulators
    Publication number: 20020138862
    Abstract: The present invention provides mice that have had their PTP-1B genes disrupted by targeted homologous recombination. The mice have no detectable PTP-1B protein, yet appear to be physiologically normal. However, in the fed state on a normal diet, the mice have half the level of circulating insulin as their wild-type littermates. In glucose and insulin tolerance tests, the mice show an increased insulin sensitivity. When fed a high fat, high carbohydrate diet, the mice show a resistance to weight gain as compared to their wild-type littermates.
    Type: Application
    Filed: July 30, 2001
    Publication date: September 26, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Brian Kennedy, Paul Payette, Michael Gresser, Chidambaram Ramachandran, Michel Tremblay, Mounib Elchebly
  • Sustained release drug dispersion delivery device
    Publication number: 20020136744
    Abstract: The present invention is related to a drug delivery device, that is pH insensitive, for the sustained in situ production and release of a dispersion, in an environment of use, which comprises
    Type: Application
    Filed: March 12, 2002
    Publication date: September 26, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Michael W. McGlynn, Mandana Asgharnejad
  • Substituted piperidines as melanocortin-4 receptor agonists
    Publication number: 20020137664
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 26, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Khaled J. Barakat, Ravi P. Nargund, Brenda L. Palucki, Arthur A. Patchett, Iyassu Sebhat, Zhixiong Ye, Leonardus H.T. Van Der Ploeg
  • Combination of a GABAA &agr;5 inverse agonist and a muscarinic agonist
    Patent number: 6455552
    Abstract: A combination of a muscarinic agonist and an inverse agonist of the GABAA &agr;5 receptor subtype useful in treating neurodegenerative conditions such as Alzheimer's Disease is disclosed.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: September 24, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Gerard Raphael Dawson
  • Human &agr;4 receptor subunit of the GABA-A receptor
    Patent number: 6455276
    Abstract: The present invention provides nucleotide sequences encoding the &agr;4 and &dgr; subunits of the human GABAA receptor, preparations of &agr;4 and &dgr; receptor subunit proteins, preparations of receptors including &agr;4 or &dgr; polypeptides, expression vectors including the nucleotide sequences, stably co-transfected eukaryotic cells and methods of their preparation and methods of screening for and designing medicaments which act upon the GABAA receptor.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: September 24, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity
    Patent number: 6455548
    Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: September 24, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Jennifer Chee, Jill N. Johanson, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht
  • Pyrazinone thrombin inhibitors
    Patent number: 6455532
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: A is  wherein Y1 and Y2 are independently hydrogen, C1-4 alkyl, C1-4 alkoxy, FuHvC(CH2)0-1 O—, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1, C3-7 cycloalkyl, thio C1-4 alkyl, C1-4 sulfinylalkyl, C1-4 sulfonylalkyl, halogen cyano, or trifluoromethyl, and wherein b is 0 or 1.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: September 24, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Christopher S. Burgey, Kyle A. Robinson, Peter D. Williams, Craig Coburn, Terry A. Lyle, Philip E. Sanderson
  • Adhesion receptor antagonists
    Patent number: 6455529
    Abstract: Compounds of the formula I in which R1, R2 and R3 have the stated meanings, and their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporoses, oncoses, stroke, myocardial infarct, ischemias, inflammations, arteriosclerosis and osteolytic disorders.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: September 24, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Joachim Gante, Hörst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
  • Dioxane derivatives, and liquid-crystalline medium
    Publication number: 20020130300
    Abstract: The invention relates to novel dioxane derivatives of the formula I
    Type: Application
    Filed: August 6, 2001
    Publication date: September 19, 2002
    Applicant: Merck GmbH
    Inventors: Matthias Bremer, Peer Kirsch, Sabine Schoen, Detlef Pauluth, Kazuaki Tarumi, Georg Lussem, Michael Heckmeier, Joachim Krause
  • Thienopyrimidines
    Publication number: 20020132818
    Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.
    Type: Application
    Filed: May 16, 2002
    Publication date: September 19, 2002
    Applicant: Merck Patent GmbH
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Polyesters containing (meth)acrylate end groups
    Publication number: 20020132961
    Abstract: The invention describes polyesters containing (meth)acrylate end groups, of the general formula (I) CH2═CRCOO—PE—OCOCR═CH2 where R=CH3 or H, where PE=[—A—OCO—B—COO—]m—A—, [—CHR′—COO—]n—A—[—OCOCHR′—]n, or combinations thereof, in which A is an alkylidene radical having 2-20 carbon atoms or an alkoxylidene radical having 2-1000, preferably 2-500, alkoxylidene units, B is a saturated alkylidene radical having 2-10 carbon atoms, R′ is H or CH3, m is 1-100, n is 1-100, and, if both m and n are present, the sum m+n is 2-200, where the polyesters containing (meth)acrylate end groups are characterised in that a) the content of short-chain di(meth)acrylates (II) CH2═CRCOO—A—OCOCR═CH2 is <5% by weight, b) the content of hydroxyl groups is <0.25 mol/mol of (meth)acrylate, and c) the APHA color number is <200.
    Type: Application
    Filed: January 14, 2002
    Publication date: September 19, 2002
    Applicant: Merck Patent GmbH
    Inventors: Werner Siol, Peter Pokinskyj
  • Apparatus for gripping microplates
    Patent number: 6449827
    Abstract: An apparatus suitable for securely gripping and holding a microplate or other containers during robotic de-lidding operations. A microplate placed on the apparatus is held by a vacuum drawn through the base thereof, allowing the lid of the microplate to be removed without movement of the plate. Afterwards, the vacuum can be discontinued and the plate removed from the apparatus.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: September 17, 2002
    Assignee: Merck & Co., Inc
    Inventors: Glenn A. Clarke, Marc N. Feiglin, Gary S. Kath, Gregory W. King
  • Transgenic mouse expressing non-native wild-type and familial Alzheimer's Disease mutant presenilin 1 protein on native presenilin 1 null background
    Patent number: 6452065
    Abstract: The present invention relates to a transgenic non-human animal embryo lacking native presenilin 1 and a transgenic non-human animal having only a non-native presenilin 1. The transgenic animals and cells derived therefrom can be used in the study of the expression pattern, activity and modulators of presenilin 1, in the study of the role of presenilin 1 in Alzheimer's Disease and in the study of disorders of the central nervous system.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: September 17, 2002
    Assignees: Merck & Co., Inc., Johns Hopkins University
    Inventors: Hui Zheng, Ping Jiang, Su Qian, Leonardus H. T. Van Der Ploeg, Philip Chun-Ying Wong, Sangram S. Sisodia